Metalloproteinases in hypertension and cardiac disease: differential expression and mutual regulation

Bosonea, Ana-Maria; Wang, Xiang; Odenbach, Jeffrey; Fernández-Patrón, Carlos

doi:10.1016/j.ddmod.2011.02.001

Cited by 4 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Encouraging results have been reported for doxycycline (MMP inhibitor) in reducing adverse LV remodeling in ST-segment elevation myocardial infarction (STEMI) patients (Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling TIPTOP trial) [105] and for metformin (AMPK activator) in reducing left ventricular mass indexed to height in non-diabetic patients with coronary artery disease (MET-REMODEL trial) [108]. These results add to overwhelming evidence implicating MMPs and AMPK in the pathogenesis of adverse cardiac remodeling in hypertension, myocardial infarction, and heart failure [59,61,[110][111][112][113][114][115][116][117][118][119][120] (all of which are comorbidities in COVID-19).…”

Section: Improving Metabolism Through Manipulation Of the Possibly Synergic Or Cooperative Actions Of Mmps Cytokines And Ampk Pathways Onmentioning

confidence: 99%

Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis

Hardy

Fernández-Patrón

2021

Biomolecules

Self Cite

View full text Add to dashboard Cite

Many individuals infected with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) develop no or only mild symptoms, but some can go on onto develop a spectrum of pathologies including pneumonia, acute respiratory distress syndrome, respiratory failure, systemic inflammation, and multiorgan failure. Many pathogens, viral and non-viral, can elicit these pathologies, which justifies reconsidering whether the target of therapeutic approaches to fight pathogen infections should be (a) the pathogen itself, (b) the pathologies elicited by the pathogen interaction with the human host, or (c) a combination of both. While little is known about the immunopathology of SARS-CoV-2, it is well-established that the above-mentioned pathologies are associated with hyper-inflammation, tissue damage, and the perturbation of target organ metabolism. Mounting evidence has shown that these processes are regulated by endoproteinases (particularly, matrix metalloproteinases (MMPs)). Here, we review what is known about the roles played by MMPs in the development of COVID-19 and postulate a mechanism by which MMPs could influence energy metabolism in target organs, such as the lung. Finally, we discuss the suitability of MMPs as therapeutic targets to increase the metabolic tolerance of the host to damage inflicted by the pathogen infection, with a focus on SARS-CoV-2.

show abstract

Section: Improving Metabolism Through Manipulation Of the Possibly Synergic Or Cooperative Actions Of Mmps Cytokines And Ampk Pathways Onmentioning

confidence: 99%

Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis

Hardy

Fernández-Patrón

2021

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

FoxO1 is required for high glucose-dependent cardiac fibroblasts into myofibroblast phenoconversion

Vivar

Anfossi

Humeres

et al. 2021

Cellular Signalling

View full text Add to dashboard Cite

Urinary MMP-7: A Predictive, Noninvasive Early Marker for Chronic Kidney Disease Development in Patients with Hypertension

Sarangi

Tripathy

Bahinipati

et al. 2022

Laboratory Medicine

View full text Add to dashboard Cite

Objective Upregulation of matrix metalloproteinase-7 (MMP-7) is associated with hypertension and kidney fibrosis, which can progress to chronic kidney disease (CKD). Currently, kidney fibrosis is only detectable by an invasive procedure. Therefore, we set out to determine whether MMP-7 can act as a noninvasive biomarker in patients with hypertension to enable early detection of kidney fibrosis. Materials and Methods Diagnosed patients with hypertension and control patients were sampled. We diagnosed CKD using clinical and laboratory parameters. Serum urea, creatinine, urinary microalbumin, the albumin-to-creatinine ratio, and urinary MMP-7 were analyzed. Results The 195 patients with hypertension had significantly elevated MMP-7. Of these patients, 166 had MMP-7 >25.8 μg/L, whereas only 29 had MMP-7 <25.8 μg/L. Thirty-two patients with hypertension showed features of CKD, all of whom had urinary MMP-7 >25.8 μg/L. However, the urinary MMP-7 level did not differ with the severity of CKD or with the duration of hypertension. Conclusion Elevated urinary MMP-7 can be a potential noninvasive, early indicator in patients with hypertension progressing to CKD, thus enabling early therapeutic intervention.

show abstract

Metalloproteinases in hypertension and cardiac disease: differential expression and mutual regulation

Cited by 4 publications

References 57 publications

Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis

Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis

FoxO1 is required for high glucose-dependent cardiac fibroblasts into myofibroblast phenoconversion

Urinary MMP-7: A Predictive, Noninvasive Early Marker for Chronic Kidney Disease Development in Patients with Hypertension

Contact Info

Product

Resources

About